Ticagrelor With or Without Aspirin After Complex PCI

[1]  Samin K. Sharma,et al.  Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. , 2020, Journal of the American College of Cardiology.

[2]  Samin K. Sharma,et al.  Ticagrelor with or without Aspirin in High-Risk Patients after PCI. , 2019, The New England journal of medicine.

[3]  A. Colombo,et al.  Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention. , 2019, International journal of cardiology.

[4]  P. Serruys,et al.  Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. , 2019, European heart journal.

[5]  G. Levine,et al.  ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. , 2018, Journal of the American College of Cardiology.

[6]  G. Giustino,et al.  Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation , 2018, Expert review of cardiovascular therapy.

[7]  G. Stone,et al.  Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. , 2018, International journal of cardiology.

[8]  U. Baber.  Defining PCI complexity in the contemporary DES era: Clarity or confusion? , 2018, International journal of cardiology.

[9]  Deepak L. Bhatt,et al.  Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention , 2018, Nature Reviews Cardiology.

[10]  R. Mehran,et al.  Navigating the complexity of percutaneous coronary intervention in patients at high risk for bleeding. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  M. Morice,et al.  Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[12]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[13]  G. Stone,et al.  Percutaneous Coronary Intervention of Saphenous Vein Graft , 2017, Circulation. Cardiovascular interventions.

[14]  G. Stone,et al.  Angiographic predictors of 2‐year stent thrombosis in patients receiving drug‐eluting stents: Insights from the ADAPT‐DES study , 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[15]  S. Pocock,et al.  Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. , 2016, American heart journal.

[16]  Deepak L. Bhatt,et al.  Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. , 2016, Journal of the American College of Cardiology.

[17]  P. Serruys,et al.  Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. , 2016, JACC. Cardiovascular interventions.

[18]  I. Palacios,et al.  Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention , 2016, Circulation.

[19]  S. Pocock,et al.  Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. , 2016, JACC. Cardiovascular interventions.

[20]  S. Pocock,et al.  Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. , 2016, Journal of the American College of Cardiology.

[21]  P. Serruys,et al.  Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. , 2016, JACC. Cardiovascular interventions.

[22]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[23]  Peter L Duffy,et al.  Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. , 2015, Journal of the American College of Cardiology.

[24]  S. Windecker,et al.  Stable coronary artery disease: revascularisation and invasive strategies , 2015, The Lancet.

[25]  R. Mehran,et al.  DAPT duration after DES: what is the "mandatory" duration? , 2015, Journal of the American College of Cardiology.

[26]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[27]  Antonio Colombo,et al.  Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.

[28]  G. Stone,et al.  Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes Pooled Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Tria , 2014 .

[29]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[30]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[31]  Jeroen J. Bax,et al.  Third universal definition of myocardial infarction. , 2012, Global heart.

[32]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[33]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[34]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[35]  K. Mann,et al.  Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. , 1991, Annals of internal medicine.